After a slow couple of years, there are signs that biotech M&A activity is coming back into vogue, and a series of small transactions announced in the last few days pr
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh